Stay updated with breaking news from Open Orphan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hvivo said it expects to achieve its revenue guidance for 2023 despite industry wide delays in UK clinical trial approvals by the Medicines and Healthcare products Regulatory Authority (MHRA).
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/irishtimes/VSZHJZKUBC6U4E5Q5K76AMQFNI.jpg)
Dublin and London-listed pharma services company has seen its order book grow 11% in first half from same period in 2022
HVIVO plc £13.1m contract to develop an influenza B virus challenge model
Hvivo will conduct a study to find an influenza B dose that creates a safe infection, before launching a human challenge trial next year.
AI analysis of unique human challenge trial data provides unparalleled insights into influenza infectionNovel influenza drug targets identified faster and more cost-effectively using AILONDON, UK / ACCESSWIRE / June 29,